Novel Agents in Multiple Myeloma
Author:
Publisher
Ovid Technologies (Wolters Kluwer Health)
Subject
Cancer Research,Oncology
Reference101 articles.
1. Transplantation for myeloma—now or later?;N Engl J Med,2017
2. Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study;Leukemia,2017
3. Emerging options in multiple myeloma: targeted, immune, and epigenetic therapies;Hematol Am Soc Hematol Educ Program,2017
4. Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin's lymphoma;N Engl J Med,2018
5. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas;N Engl J Med,2010
Cited by 21 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Efficacy of daratumumab on multiple myeloma patients with renal insufficiency: a systematic review and meta-analysis;Hematology;2024-09-09
2. Current Strategies and Future Directions in Multiple Myeloma: Disease Overview and Pathophysiology, Conventional Treatments and Emerging Therapies, Challenges and Innovations in Management;European Journal of Medical and Health Research;2024-09-01
3. CTPS1 is a novel therapeutic target in multiple myeloma which synergizes with inhibition of CHEK1, ATR or WEE1;Leukemia;2023-10-28
4. Real-world treatment patterns, healthcare resource use and disease burden in patients with multiple myeloma in Europe;Future Oncology;2023-10
5. Identification and study of cuproptosis-related genes in prognostic model of multiple myeloma;Hematology;2023-08-23
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3